Sentences with phrase «clinical data from»

Using clinical data from 137 caregiver - child dyads, the main goal of the current study was to test the psychometric properties of an adapted version of the Crowell Procedure among preschoolers.

David Koppers will complement the symposium with clinical data from group therapy: He will present the results of a cohort study investigating the effectiveness of short term group schema therapy in a mixed personality disorder sample with or without comorbid depression.

Created SAS datasets of clinical data from clinical databases; create status and efficacy datasets; create project specific macros and formats; load client data from other platforms and other software packages; prepared data to be sent to clients

Perform the tasks of collecting and entering clinical data from paper and electronic sources into a transplant electronic medical record by following specific guidelines

No offense, but GE was developing something like this several years ago, using clinical data from Intermountain Health, which has lower costs than other systems (because it has control of income as well as outgo, therefore an incentive to limit the latter).

The VetCompass ™ Programme collates de-identified clinical data from primary - care veterinary practices in the UK for epidemiological research.

The formulation is based on clinical data from Dr. Shelton's use in her veterinary practice.

OXGN is getting closer to present clinical data from it's late stage phase II and phase II / III trials.

The genes were identified through population - and genome - wide linkage scans and association analyses of at - risk haplotypes utilizing genetic and clinical data from the 17,000 participants in deCODE's obesity program in Iceland.

He is also interested in the capture of precise clinical data from clinicians using effective user interfaces.

The authors acknowledge that a limitation of their study is that it is based on clinical data from Mexico, which has much less summer - winter variation than Europe, thus affecting mosquitoes» survival and overwintering.

Through seminars, workshops, working groups, and online consensus - building projects supported by immunological and clinical data from cancer immunotherapy trials, the Consortium works to address several of the key issues facing the cancer immunotherapy field.

Analyzes whole genome and detailed clinical data from nearly 300,000 Icelanders Finds several novel variations in the sequence of the human genome modulating cholesterol levels Five variants are also causally linked to increased risk of coronary artery disease Shows...

A new analysis of clinical data from the TRACK - HD and COHORT studies proposes a way to design of clinical trials designed to delay the onset of HD, rather than treating symptoms after they occur.

Together with data from the previously reported Cohort 2 (AIS - A injuries administered 10 million AST - OPC1 cells), updated clinical data from the SCiStar study is set forth in the tables below:

Building on clinical data from several single - agent immunotherapy clinical trials, and by engaging scientists with unique and complementary expertise from eight institutions and three industry partners, the BEAT - HIV Collaboratory's central mission will be to develop and test innovative combined immunotherapy strategies to eradicate and / or permanently suppress HIV replication in the absence of ART.

Researchers are building a database of DNA sequence, functional and epigenomic information, and clinical data from studies on type 2 diabetes and its macro - and microvascular complications, and creating analytic tools to analyze these data.

The scientists obtained stool samples, diet information and clinical data from 91 pregnant women during the first and third trimesters.

They will also be invited to answer questions about their health history and status, share their genomic and other biological information through simple blood and urine tests, and grant access to their clinical data from electronic health records.

«We will be able to link all of our group's discoveries using blood samples and clinical data from the extensive NHLBI - sponsored Multi-Ethnic Study of Atherosclerosis (MESA) cohort, a large longitudinal cohort established in 2000 to study factors contributing to cardiovascular disease progression.

Randy Mills, president of the California Institute for Regenerative Medicine told California Stem Cell Report that «the latest clinical data from ViaCyte are very encouraging and a clear sign of progress.»

Clinical data from Incyte and BMS has demonstrated improved outcomes from the use of their IDO1 inhibitors in combination with PD1 / PDL1 antibody therapies.

LA JOLLA — The Salk Institute, which hosts a National Cancer Institute (NCI)-- designated cancer center and Indivumed GmbH, a world leading cancer research company today announce a multi-year strategic alliance to secure, preserve and analyze human cancer tissue and annotated clinical data from consenting patients around the world, enabling the most cutting - edge basic and translational research in cancer.

The findings from this one cell line are also inconsistent with clinical data from preimplantation genetic diagnosis, further suggesting that the stem cell assay may not wholly reflect what happens during human development.

In its population gene discovery work, deCODE has mapped several key genes linked to obesity and has gathered detailed genotypic and clinical data from more than 10,000 adult volunteers among the Icelandic population.

So we'll be writing a lot of papers and then we'll be working with the patients to perfect other details of the exoskeleton and to get more clinical data from them.

In order to investigate whether a healthy lifestyle can mitigate genetic risk, the multi-institutional research team analyzed genetic and clinical data from more than 55,000 participants in four large - scale studies.

Researchers were able to access CSF samples from the deprenyl and tocopherol antioxidative therapy of Parkinsonism (DATATOP) study, which is the largest cohort assembled to date with longitudinal collection of biological fluids and clinical data from PD patients.

The NNRD holds routinely recorded clinical data from all English NHS neonatal units from 2012 onwards.

At a 5 April hearing in Brazil's Federal Senate, Chierice charged that the government - sponsored studies are being done in «bad faith,» and stated that his group is obtaining clinical data from overseas.

In a paper published in March, he and his colleagues examined samples from the Cancer Genome Atlas, a collection of genetic and clinical data from thousands of people with cancer.

«Our approach does not rely on model systems but on DNA samples and clinical data from human patients.

The researchers from the University of Exeter analysed clinical data from over 4,500 patients across the UK who were later diagnosed with bowel cancer.

«[T] he GDC will accept submissions of cancer genomic and clinical data from researchers around the world who wish to share their data broadly,» the NIH explained on its website.

In 2016, the FDA teamed up with Flatiron Health, a $ 1.2 billion New York - based healthcare technology startup that collects clinical data from cancer patients — such as what medications a patient has taken and how he or she has responded to them.

Not exact matches

In particular, the complaint alleges that throughout the Class Period, defendants made materially false and / or misleading statements and / or failed to disclose that (1) the trials for GED - 0301 suffered from fatal design defects, such that GED - 0301 had failed to demonstrate meaningful clinical efficacy; (2) the growth of Otezla sales had dramatically slowed during Celgene's third fiscal quarter of 2017; and (3) the clinical and nonclinical pharmacology data in Celgene's new drug application («NDA») for Ozanimod were insufficient to permit a complete review by the FDA, which resulted in the FDA issuing a refusal to file letter to Celgene regarding the NDA.

Shorn of human weaknesses like the need to eat or sleep, computers are now speed - reading through not only the vast academic literature but also CT scans, electronic medical records, and mountains of data from clinical trials and genomic studies.

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

«IBM and the FDA will explore the exchange of owner mediated data from several sources, such as Electronic Medical Records, clinical trials, genomic data, and health data from mobile devices, wearables and the «Internet of Things,»» said the company in a press release.

Actual results and the timing of events could differ materially from those anticipated in the forward - looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: the uncertain timing of, and risks relating to, the executive search process; risks related to the potential failure of eptinezumab to demonstrate safety and efficacy in clinical testing; Alder's ability to conduct clinical trials and studies of eptinezumab sufficient to achieve a positive completion; the availability of data at the expected times; the clinical, therapeutic and commercial value of eptinezumab; risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Alder's development and commercialization activities; the sufficiency of Alder's capital and other resources; market competition; changes in economic and business conditions; and other factors discussed under the caption «Risk Factors» in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sec.gov.

MEDIAL EARLYSIGN SHOWS AI AND EHR DATA CAN BE USED FOR EARLY DETECTION: Researchers from Medial EarlySign, a provider of machine - learning solutions, found that the combination of machine learning technology and electronic health record (EHR) data can be more effective than current clinical tools in identifying the risk of kidney damage in diabetics.

Its trove of data allowed the company to mine the population for genetic variants and connect those variants to clinical outcomes in diseases ranging from cancer to schizophrenia.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

«[A.I.] can help analyze large data sets from sources such as clinical trials, health records, genetic profiles, and preclinical studies; within this data, it can recognize patterns and trends and develop hypotheses at a much faster rate than researchers alone,» says Deloitte.

Lastly, Dr. Zemojtel will discuss the data obtained with the Avenio workflow from clinical research subjects with ovarian cancer.

The adaptive pathways concept applies primarily to treatments in areas of high medical need where it is difficult to collect data via traditional routes and where large clinical trials would unnecessarily expose patients who are unlikely to benefit from the medicine.

Using data from clinical food challenge studies, the VSEP has identified reference doses for the common food allergens at which 95 - 99 % of the allergic population are unlikely react (1,2).

Among 11 study participants for whom data from the oral food challenge were either inconclusive or not available, a diagnostic algorithm based on clinical history, the results of a skin - prick test, and the values for peanut - specific IgE were used to determine whether or not a participant should be considered to have peanut allergy (Fig.

We obtained clinical data regarding respondents» course of pregnancy and labor from the medical records and birth registration forms that were filled out by the midwives and obstetricians.

These virtual results are based on the actual data points derived from StriVectin's extensive clinical studies for StriVectin - SD ™ Intensive Concentrate for Stretch Marks & Wrinkles and StriVectin - SD ™ Eye Concentrate for Wrinkles.